GLP-1 Drug Exenatide Did Not Slow Parkinson's Disease in Major Clinical Trial
A definitive phase 3 trial found that weekly exenatide injections did not slow Parkinson's disease progression over two years, despite earlier promising signals.
Quick Facts
What This Study Found
In this definitive phase 3 trial, the GLP-1 receptor agonist exenatide did NOT slow Parkinson's disease progression compared to placebo. After 96 weeks, Parkinson's motor symptoms worsened by 5.7 points in the exenatide group versus 4.5 points in the placebo group on the MDS-UPDRS III scale — no meaningful difference (p=0.47).
The drug was safe and well-tolerated, with serious adverse events actually slightly lower in the exenatide group (9% vs 11%). But the primary hypothesis — that exenatide could be a disease-modifying treatment for Parkinson's — was not supported by the data.
Key Numbers
n=194 · 96 weeks · MDS-UPDRS III OFF worsening: +5.7 (exenatide) vs +4.5 (placebo) · p=0.47 · Serious adverse events: 9% vs 11% · Exenatide 2 mg/week subcutaneous
How They Did This
Phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial across 6 UK research hospitals. 194 participants with Parkinson's disease (Hoehn & Yahr stage ≤2.5, ages 25-80) were randomized 1:1 to exenatide 2 mg extended-release subcutaneous injection once weekly or placebo for 96 weeks. The primary outcome was change in MDS-UPDRS Part III motor score assessed while patients were off their dopaminergic medications, analyzed using intention-to-treat with linear mixed modeling.
Why This Research Matters
There had been enormous excitement about GLP-1 drugs potentially protecting the brain, fueled by lab studies showing neurotrophic properties and a smaller earlier trial suggesting benefits. This large, rigorous phase 3 trial is a reality check: exenatide does not appear to slow Parkinson's progression. It's an important negative result that redirects the field toward either different GLP-1 agents with better brain penetration or targeting specific patient subgroups who might still respond.
The Bigger Picture
This is one of the most important negative results in the GLP-1/neurodegeneration field. With millions taking GLP-1 drugs for diabetes and weight loss, and epidemiological data suggesting lower Parkinson's risk in those populations, the hope was that these drugs could be repurposed for brain diseases. This trial shows it's not that simple — at least not with exenatide. The research community is now looking at newer GLP-1 agonists like lixisenatide and semaglutide, which may cross the blood-brain barrier more effectively.
What This Study Doesn't Tell Us
The trial used exenatide, an older GLP-1 agonist that may have limited brain penetration compared to newer agents like semaglutide. The sample size (194) may have been underpowered to detect subtle effects or benefits in subgroups. The study enrolled participants relatively early in their disease course (Hoehn & Yahr ≤2.5). COVID-19 pandemic overlap may have affected follow-up and participation.
Questions This Raises
- ?Would newer GLP-1 agonists like semaglutide, which may have better brain penetration, produce different results in Parkinson's disease?
- ?Are there specific genetic or clinical subgroups of Parkinson's patients who might still benefit from GLP-1 receptor activation?
- ?Do the epidemiological associations between GLP-1 drug use and reduced Parkinson's risk reflect something other than direct neuroprotection?
Trust & Context
- Key Stat:
- p=0.47 No significant difference in Parkinson's motor progression between exenatide and placebo over 96 weeks — the drug did not modify disease course
- Evidence Grade:
- This is a well-designed phase 3, double-blind, randomized, placebo-controlled trial published in The Lancet — the gold standard for clinical evidence. The negative result is just as informative as a positive one.
- Study Age:
- Published in 2025 in The Lancet. This is the most current and definitive trial on exenatide for Parkinson's, superseding earlier positive signals from smaller studies.
- Original Title:
- Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.
- Published In:
- Lancet (London, England), 405(10479), 627-636 (2025)
- Authors:
- Vijiaratnam, Nirosen(2), Girges, Christine(2), Auld, Grace, McComish, Rachel, King, Alexa, Skene, Simon S, Hibbert, Steve, Wong, Alan, Melander, Sabina, Gibson, Rachel, Matthews, Helen, Dickson, John, Carroll, Camille, Patrick, Abigail, Inches, Jemma, Silverdale, Monty, Blackledge, Bethan, Whiston, Jessica, Hu, Michele, Welch, Jessica, Duncan, Gordon, Power, Katie, Gallen, Sarah, Kerr, Jacqueline, Chaudhuri, K Ray, Batzu, Lucia, Rota, Silvia, Jabbari, Edwin, Morris, Huw, Limousin, Patricia, Greig, Nigel, Li, Yazhou, Libri, Vincenzo, Gandhi, Sonia, Athauda, Dilan, Chowdhury, Kashfia, Foltynie, Tom
- Database ID:
- RPEP-13921
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
Why did scientists think a diabetes drug might help Parkinson's disease?
Laboratory studies showed that GLP-1 receptor agonists like exenatide have neurotrophic properties — they support nerve cell survival and growth. A smaller earlier trial had also suggested motor benefits. Plus, large population studies found that people taking GLP-1 drugs for diabetes seemed to develop Parkinson's at lower rates. These converging signals made a definitive trial necessary.
Does this mean all GLP-1 drugs are useless for Parkinson's?
Not necessarily. Exenatide is an older GLP-1 drug that may not penetrate the brain very well. Newer agents like semaglutide and lixisenatide may reach the brain more effectively. Several trials with these newer drugs are underway or planned. This result specifically applies to exenatide, not the entire drug class.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13921APA
Vijiaratnam, Nirosen; Girges, Christine; Auld, Grace; McComish, Rachel; King, Alexa; Skene, Simon S; Hibbert, Steve; Wong, Alan; Melander, Sabina; Gibson, Rachel; Matthews, Helen; Dickson, John; Carroll, Camille; Patrick, Abigail; Inches, Jemma; Silverdale, Monty; Blackledge, Bethan; Whiston, Jessica; Hu, Michele; Welch, Jessica; Duncan, Gordon; Power, Katie; Gallen, Sarah; Kerr, Jacqueline; Chaudhuri, K Ray; Batzu, Lucia; Rota, Silvia; Jabbari, Edwin; Morris, Huw; Limousin, Patricia; Greig, Nigel; Li, Yazhou; Libri, Vincenzo; Gandhi, Sonia; Athauda, Dilan; Chowdhury, Kashfia; Foltynie, Tom. (2025). Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.. Lancet (London, England), 405(10479), 627-636. https://doi.org/10.1016/S0140-6736(24)02808-3
MLA
Vijiaratnam, Nirosen, et al. "Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.." Lancet (London, 2025. https://doi.org/10.1016/S0140-6736(24)02808-3
RethinkPeptides
RethinkPeptides Research Database. "Exenatide once a week versus placebo as a potential disease-..." RPEP-13921. Retrieved from https://rethinkpeptides.com/research/vijiaratnam-2025-exenatide-once-a-week
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.